Multifocal Head and Neck Paraganglioma Evaluated with Different PET Tracers: Comparison Between Fluorine-18-Fluorodeoxyglucose and Gallium-68-Somatostatin Receptor PET/CT

Castaldi, Paola; Treglia, Giorgio; Rufini, Vittoria

doi:10.1007/s13139-013-0204-x

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small meningiomas could be localized by [ 68 Ga]Ga‐DOTA‐TOC, while diagnostic performance of [ 18 F]FDG was limited because of the high physiological uptake and consequently poor image contrast . The detection rate was higher when using [ 68 Ga]Ga‐DOTA‐NOC and [ 68 Ga]Ga‐DOTA‐TATE as compared with [ 18 F]FDG in patients affected respectively by head and neck paraganglioma and metastasized merkel cell carcinoma . [ 68 Ga]Ga‐DOTA‐TOC was found superior to [ 18 F]FDG and could predict histology in suspected bronchopulmonary carcinoids; it was more sensitive and specific in differentiating the pulmonary carcinoids from other tumours .…”

Section: Targeted Imagingmentioning

confidence: 99%

Continued rapid growth in ⁶⁸Ga applications: update 2013 to June 2014

Velikyan

2015

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The worldwide utilization of (68) Ga-radionuclide for the fundamental research and clinical applications is growing exponentially. A broad range of (68) Ga-based imaging agents has been explored during recent years. The development of new clinically useful agents is encouraged by many factors; for example, increasing role of positron emission tomography (PET) in nuclear medicine, discovery of new biomarkers, accessibility of (68) Ga, and establishment of PET radiopharmaceutical regulation and legislation. The focus of this review resides on the reports regarding (68) Ga-related research and applications published during 2013 to June 2014.

show abstract

Section: Targeted Imagingmentioning

confidence: 99%

Continued rapid growth in ⁶⁸Ga applications: update 2013 to June 2014

Velikyan

2015

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…For instance, in a case of a multifocal HNP, 68 Ga-DOTANOC PET/CT enabled the detection of additional lesions in comparison with 18 F-FDG PET/CT, highlighting the excellent staging capacity of this alternative tracer [46]. Furthermore, Sharma et al [47] reported 26 patients with known or suspected HNPs who underwent 68 Ga-DOTANOC PET/CT for staging purposes.…”

Section: Somatostatin Receptor Pet Imagingmentioning

confidence: 99%

Non-18F-FDG PET/CT in the management of patients affected by HNC

Quartuccio

Caobelli

Mauro

et al. 2016

Nuclear Medicine Communications

View full text Add to dashboard Cite

PET/computed tomography with F-fluorodeoxyglucose is considered a powerful molecular imaging technique that can provide useful information in the management of patients affected by head and neck cancer. However, misleading findings have been reported because of nonspecific uptake caused by peritumoural inflammation and physiologic changes in nonmalignant tissues in the head and neck region. More specific β-emitting tracers have been introduced that can track other pathological processes. We aimed to review the existing literature performing the search until June 2015 on non-F-fluorodeoxyglucose PET tracers in head and neck cancer to highlight their role in clinical practice.

show abstract

Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas

et al. 2017

View full text Add to dashboard Cite

Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis are observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.In the present study, expression of all five somatostatin receptor (SST) subtypes, chemokine receptor CXCR4 and endothelin receptor type A (ETA) was assessed by means of immunohistochemistry in a total of 66 paraffin-embedded paraganglioma samples from 55 patients. The stainings were rated by means of the Immunoreactive Score and correlated to clinical data and to succinate dehydrogenase subunit B (SDHB) expression.SST2A was by far the most prominent receptor in the paragangliomas investigated. It was present in 89% of the tumors at a high intensity, followed by SST5, SST3, SST1 and SST4, which were detected in 47%, 35%, 35% and 13% of the samples, respectively. SDHB positive tumors exhibited significantly higher SST2A and SST3 expression as compared to SDHB negative cases. There was no correlation between SST and Ki-67 expression or grading of the tumors and no difference in SST expression between primary tumors and metastases. Cell surface expression of CXCR4 and ETA was detected only in few samples. On tumor capillaries, however, exceptionally strong staining for these two receptors was noticed in the vast majority of the tumors.In conclusion, paragangliomas are well suited for SST2A-based diagnostics and treatment modalities. An indirect targeting of these highly vascularized tumors via CXCR4 or ETA may also represent a promising future strategy.

show abstract

Multifocal Head and Neck Paraganglioma Evaluated with Different PET Tracers: Comparison Between Fluorine-18-Fluorodeoxyglucose and Gallium-68-Somatostatin Receptor PET/CT

Cited by 4 publications

References 7 publications

Continued rapid growth in ⁶⁸Ga applications: update 2013 to June 2014

Continued rapid growth in ⁶⁸Ga applications: update 2013 to June 2014

Non-18F-FDG PET/CT in the management of patients affected by HNC

Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas

Contact Info

Product

Resources

About

Multifocal Head and Neck Paraganglioma Evaluated with Different PET Tracers: Comparison Between Fluorine-18-Fluorodeoxyglucose and Gallium-68-Somatostatin Receptor PET/CT

Cited by 4 publications

References 7 publications

Continued rapid growth in 68Ga applications: update 2013 to June 2014

Continued rapid growth in 68Ga applications: update 2013 to June 2014

Non-18F-FDG PET/CT in the management of patients affected by HNC

Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas

Contact Info

Product

Resources

About

Continued rapid growth in ⁶⁸Ga applications: update 2013 to June 2014

Continued rapid growth in ⁶⁸Ga applications: update 2013 to June 2014